Export Ready — 

Zinc-organometallic framework vaccine controlled-release zn2+ regulates tumor extracellular matrix degradation potentiate efficacy of immunotherapy

Bibliographic Details
Main Author: Ding, Lin
Publication Date: 2023
Other Authors: Liang, Minli, Li, Yuanyuan, Zeng, Mei, Liu, Meiting, Ma, Wei, Chen, Fuming, Li, Chenchen, Reis, R. L., Li, Fu-Rong, Wang, Yanli
Format: Article
Language: eng
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: https://hdl.handle.net/1822/90068
Summary: Tumor extracellular matrix (ECM) not only forms a physical barrier for T cells infiltration, but also regulates multiple immunosuppressive pathways, which is an important reason for immunotherapy failure. The cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon genes (cGAS-STING) pathway plays a key role in activating CD8+ T cells, maintaining CD8+ T cells stemness and enhancing the antitumor effect. Herein, a zinc-organometallic framework vaccine (ZPM@OVA-CpG) prepared by self-assembly, which achieves site-directed release of Zn2+ in dendritic cell (DC) lysosomes and tumor microenvironment under acidic conditions, is reported. The vaccine actively targets DC, significantly enhances cGAS-STING signal, promotes DC maturation and antigen cross-presentation, and induces strong activation of CD8+ T cells. Meanwhile, the vaccine reaches the tumor site, releasing Zn2+, significantly up-regulates the activity of matrix metalloproteinase-2, degrades various collagen components of tumor ECM, effectively alleviates immune suppression, and significantly enhances the tumor infiltration and killing of CD8+ T cells. ZPM@OVA-CpG vaccine not only solves the problem of low antigen delivery efficiency and weak CD8+ T cells activation ability, but also achieves the degradation of tumor ECM via the vaccine for the first time, providing a promising therapeutic platform for the development of efficient novel tumor vaccines.
id RCAP_e60509923fde1df65c99fb8b3df7afac
oai_identifier_str oai:repositorium.sdum.uminho.pt:1822/90068
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Zinc-organometallic framework vaccine controlled-release zn2+ regulates tumor extracellular matrix degradation potentiate efficacy of immunotherapyImmunotherapyTumor extracellular matrixVaccineZinc-organometallic frameworkZn2+Tumor extracellular matrix (ECM) not only forms a physical barrier for T cells infiltration, but also regulates multiple immunosuppressive pathways, which is an important reason for immunotherapy failure. The cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon genes (cGAS-STING) pathway plays a key role in activating CD8+ T cells, maintaining CD8+ T cells stemness and enhancing the antitumor effect. Herein, a zinc-organometallic framework vaccine (ZPM@OVA-CpG) prepared by self-assembly, which achieves site-directed release of Zn2+ in dendritic cell (DC) lysosomes and tumor microenvironment under acidic conditions, is reported. The vaccine actively targets DC, significantly enhances cGAS-STING signal, promotes DC maturation and antigen cross-presentation, and induces strong activation of CD8+ T cells. Meanwhile, the vaccine reaches the tumor site, releasing Zn2+, significantly up-regulates the activity of matrix metalloproteinase-2, degrades various collagen components of tumor ECM, effectively alleviates immune suppression, and significantly enhances the tumor infiltration and killing of CD8+ T cells. ZPM@OVA-CpG vaccine not only solves the problem of low antigen delivery efficiency and weak CD8+ T cells activation ability, but also achieves the degradation of tumor ECM via the vaccine for the first time, providing a promising therapeutic platform for the development of efficient novel tumor vaccines.This project was supported by the Shenzhen Science and Technology Program (Grant No. RCBS20210609104513023), Guangdong Basic and Applied Basic Research Foundation (No. 2022A1515010056, No. 2021A1515110657), National Key Research and Development Program of China (No. 2022YFC2305000), National Natural Science Foundation of China (No. 82001755).WileyUniversidade do MinhoDing, LinLiang, MinliLi, YuanyuanZeng, MeiLiu, MeitingMa, WeiChen, FumingLi, ChenchenReis, R. L.Li, Fu-RongWang, Yanli2023-072023-07-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/1822/90068engDing L., Liang M. L., Li Y. Y., Zeng M., Liu M. T., Ma W., Chen F. M., Li C. C., Reis R. L., Li F. R., Wang Y. L. Zinc-Organometallic Framework Vaccine Controlled-Release Zn2+ Regulates Tumor Extracellular Matrix Degradation Potentiate Efficacy of Immunotherapy, Advanced Science, Vol. 10, Issue 27, pp. 2302967, doi:https://doi.org/10.1002/advs.202302967, 20232198-384410.1002/advs.20230296737439462https://onlinelibrary.wiley.com/doi/10.1002/advs.202302967info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2024-05-11T05:31:04Zoai:repositorium.sdum.uminho.pt:1822/90068Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T15:21:01.534793Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Zinc-organometallic framework vaccine controlled-release zn2+ regulates tumor extracellular matrix degradation potentiate efficacy of immunotherapy
title Zinc-organometallic framework vaccine controlled-release zn2+ regulates tumor extracellular matrix degradation potentiate efficacy of immunotherapy
spellingShingle Zinc-organometallic framework vaccine controlled-release zn2+ regulates tumor extracellular matrix degradation potentiate efficacy of immunotherapy
Ding, Lin
Immunotherapy
Tumor extracellular matrix
Vaccine
Zinc-organometallic framework
Zn2+
title_short Zinc-organometallic framework vaccine controlled-release zn2+ regulates tumor extracellular matrix degradation potentiate efficacy of immunotherapy
title_full Zinc-organometallic framework vaccine controlled-release zn2+ regulates tumor extracellular matrix degradation potentiate efficacy of immunotherapy
title_fullStr Zinc-organometallic framework vaccine controlled-release zn2+ regulates tumor extracellular matrix degradation potentiate efficacy of immunotherapy
title_full_unstemmed Zinc-organometallic framework vaccine controlled-release zn2+ regulates tumor extracellular matrix degradation potentiate efficacy of immunotherapy
title_sort Zinc-organometallic framework vaccine controlled-release zn2+ regulates tumor extracellular matrix degradation potentiate efficacy of immunotherapy
author Ding, Lin
author_facet Ding, Lin
Liang, Minli
Li, Yuanyuan
Zeng, Mei
Liu, Meiting
Ma, Wei
Chen, Fuming
Li, Chenchen
Reis, R. L.
Li, Fu-Rong
Wang, Yanli
author_role author
author2 Liang, Minli
Li, Yuanyuan
Zeng, Mei
Liu, Meiting
Ma, Wei
Chen, Fuming
Li, Chenchen
Reis, R. L.
Li, Fu-Rong
Wang, Yanli
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade do Minho
dc.contributor.author.fl_str_mv Ding, Lin
Liang, Minli
Li, Yuanyuan
Zeng, Mei
Liu, Meiting
Ma, Wei
Chen, Fuming
Li, Chenchen
Reis, R. L.
Li, Fu-Rong
Wang, Yanli
dc.subject.por.fl_str_mv Immunotherapy
Tumor extracellular matrix
Vaccine
Zinc-organometallic framework
Zn2+
topic Immunotherapy
Tumor extracellular matrix
Vaccine
Zinc-organometallic framework
Zn2+
description Tumor extracellular matrix (ECM) not only forms a physical barrier for T cells infiltration, but also regulates multiple immunosuppressive pathways, which is an important reason for immunotherapy failure. The cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon genes (cGAS-STING) pathway plays a key role in activating CD8+ T cells, maintaining CD8+ T cells stemness and enhancing the antitumor effect. Herein, a zinc-organometallic framework vaccine (ZPM@OVA-CpG) prepared by self-assembly, which achieves site-directed release of Zn2+ in dendritic cell (DC) lysosomes and tumor microenvironment under acidic conditions, is reported. The vaccine actively targets DC, significantly enhances cGAS-STING signal, promotes DC maturation and antigen cross-presentation, and induces strong activation of CD8+ T cells. Meanwhile, the vaccine reaches the tumor site, releasing Zn2+, significantly up-regulates the activity of matrix metalloproteinase-2, degrades various collagen components of tumor ECM, effectively alleviates immune suppression, and significantly enhances the tumor infiltration and killing of CD8+ T cells. ZPM@OVA-CpG vaccine not only solves the problem of low antigen delivery efficiency and weak CD8+ T cells activation ability, but also achieves the degradation of tumor ECM via the vaccine for the first time, providing a promising therapeutic platform for the development of efficient novel tumor vaccines.
publishDate 2023
dc.date.none.fl_str_mv 2023-07
2023-07-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://hdl.handle.net/1822/90068
url https://hdl.handle.net/1822/90068
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Ding L., Liang M. L., Li Y. Y., Zeng M., Liu M. T., Ma W., Chen F. M., Li C. C., Reis R. L., Li F. R., Wang Y. L. Zinc-Organometallic Framework Vaccine Controlled-Release Zn2+ Regulates Tumor Extracellular Matrix Degradation Potentiate Efficacy of Immunotherapy, Advanced Science, Vol. 10, Issue 27, pp. 2302967, doi:https://doi.org/10.1002/advs.202302967, 2023
2198-3844
10.1002/advs.202302967
37439462
https://onlinelibrary.wiley.com/doi/10.1002/advs.202302967
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833595259812052992